

# **TRIANEX<sup>®</sup> 0.05% (Triamcinolone Acetonide Ointment, USP)** **Now Available from Promius Pharma, LLC**



Princeton, NJ – March 5, 2015 – Promius Pharma, LLC, has acquired the rights to market and distribute **Trianex<sup>®</sup> 0.05% (Triamcinolone Acetonide Ointment, USP)** in the United States from CMP Pharma, Inc. **Trianex Ointment**, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of a cream.

“We are pleased to add Trianex into the Promius Pharma family of topical corticosteroid products, which already features Cloderm<sup>®</sup> (clocortolone pivalate) Cream, 0.1% and its authorized generic. The portfolio addition of Trianex offers an effective treatment option for chronic, widespread dermatoses, with an excellent safety profile,” said Eric Shenloogian, Associate Director – Marketing for Promius Pharma.

**Trianex Ointment** will be available in a 430 gram jar and features a proprietary cream-like formulation. It will be the only ointment to offer this combination, making it an appealing option for those patients with inflammatory skin conditions that cover large areas and who don't like the typical greasy feel of ointments.

“The look and feel of the white ointment and size are significant,” explained Shenloogian, “because patients tell us they would rather not use greasy ointments, especially when they have a large area to cover. By offering a large (430 gram) jar, instead of a typical small tube, we provide a convenient option for patients to use Trianex.”

Also, to make it more affordable, Trianex Ointment offers a significant savings program to all eligible insured patients who receive a prescription for the 430 gram jar.\*

With **Trianex Ointment** and Cloderm Cream, Promius Pharma now offers options to cover a wide range of patients with inflammatory skin conditions.

###

## **Trianex Indication and Important Safety Information**

Trianex<sup>®</sup> 0.05% (Triamcinolone Acetonide Ointment, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with Trianex Ointment include burning, itching, irritation, dryness, and folliculitis. Trianex Ointment is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

**Please visit [www.trianexointment.com](http://www.trianexointment.com) for Full Prescribing Information.**

**\*Please see patient savings card for eligibility requirements.**

### **Cloderm Indication and Important Safety Information**

Cloderm<sup>®</sup> Cream and Clocortolone Pivalate Cream, 0.1%, are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with Cloderm Cream and Clocortolone Pivalate Cream, 0.1%, include burning, itching, irritation, dryness, and folliculitis. Cloderm Cream and Clocortolone Pivalate Cream, 0.1%, are contraindicated in patients who are hypersensitive to any of the ingredients of these products. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

**Please visit [www.clodermcream.com](http://www.clodermcream.com) for Full Prescribing Information.**

### **About Promius Pharma, LLC**

Promius Pharma is a wholly owned, branded specialty company, of Dr. Reddy's Laboratories, Inc. It is located in Princeton, NJ. Promius Pharma is a focused, leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients. For more information visit [www.promiuspharma.com](http://www.promiuspharma.com).

Trianex is a registered trademark of CMP Pharma, Inc.  
Cloderm<sup>®</sup> is a trademark of Coria Laboratories, LTD.  
© 2015 Promius Pharma, LLC. All Rights Reserved.

**CONTACT:** Suzanne Lane/Anneka Ranpuria – The Lane Communications Group  
212.757.6880, [slane@thelcgroup.com](mailto:slane@thelcgroup.com), [aranpuria@thelcgroup.com](mailto:aranpuria@thelcgroup.com)